X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6924) 6924
Publication (536) 536
Book Review (167) 167
Newsletter (79) 79
Newspaper Article (23) 23
Book Chapter (22) 22
Magazine Article (16) 16
Conference Proceeding (9) 9
Dissertation (3) 3
Trade Publication Article (3) 3
Book / eBook (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
infliximab (6250) 6250
humans (5056) 5056
index medicus (3201) 3201
female (3041) 3041
male (2987) 2987
adult (2389) 2389
middle aged (2197) 2197
antibodies, monoclonal - therapeutic use (1947) 1947
treatment outcome (1939) 1939
tumor necrosis factor-alpha - antagonists & inhibitors (1720) 1720
antibodies, monoclonal - administration & dosage (1539) 1539
etanercept (1465) 1465
adalimumab (1441) 1441
gastroenterology & hepatology (1403) 1403
rheumatology (1328) 1328
rheumatoid arthritis (1200) 1200
therapy (1183) 1183
aged (1133) 1133
arthritis, rheumatoid - drug therapy (1080) 1080
drug therapy (1070) 1070
antibodies, monoclonal - adverse effects (1067) 1067
dosage and administration (1043) 1043
crohn disease - drug therapy (1008) 1008
crohn's disease (992) 992
care and treatment (980) 980
crohns-disease (933) 933
inflammatory-bowel-disease (933) 933
rheumatoid-arthritis (912) 912
antirheumatic agents - therapeutic use (867) 867
efficacy (791) 791
methotrexate (765) 765
inflammatory bowel disease (746) 746
adolescent (733) 733
double-blind (712) 712
ulcerative colitis (695) 695
drug therapy, combination (693) 693
severity of illness index (688) 688
monoclonal antibodies (672) 672
risk factors (659) 659
young adult (656) 656
antirheumatic agents - administration & dosage (641) 641
retrospective studies (639) 639
pharmacology & pharmacy (627) 627
research (619) 619
drug administration schedule (604) 604
follow-up studies (585) 585
psoriasis (579) 579
safety (571) 571
dermatology (551) 551
tumor necrosis factor (543) 543
tumor necrosis factor-tnf (541) 541
patients (538) 538
arthritis (537) 537
necrosis-factor-alpha (530) 530
anti-inflammatory agents - therapeutic use (523) 523
time factors (520) 520
immunosuppressive agents - therapeutic use (517) 517
antirheumatic agents - adverse effects (495) 495
complications and side effects (484) 484
immunology (482) 482
gastrointestinal agents - therapeutic use (479) 479
disease (474) 474
colitis, ulcerative - drug therapy (473) 473
tumor necrosis factor-α (466) 466
anti-inflammatory agents - administration & dosage (458) 458
dose-response relationship, drug (443) 443
immunoglobulin g - therapeutic use (427) 427
remission induction (423) 423
gastrointestinal agents - administration & dosage (422) 422
animals (421) 421
inflammation (419) 419
receptors, tumor necrosis factor - therapeutic use (419) 419
antibodies, monoclonal, humanized (415) 415
health aspects (415) 415
medicine & public health (415) 415
child (413) 413
prospective studies (407) 407
analysis (406) 406
patient outcomes (401) 401
tumor-necrosis-factor (397) 397
infliximab - therapeutic use (393) 393
trial (388) 388
inflammatory bowel diseases - drug therapy (384) 384
infliximab - administration & dosage (376) 376
psoriasis - drug therapy (372) 372
diagnosis (370) 370
medicine, general & internal (370) 370
tnf-alpha (369) 369
tumor necrosis factor-alpha - immunology (367) 367
abridged index medicus (361) 361
infusions, intravenous (360) 360
remission (356) 356
ulcerative-colitis (338) 338
management (337) 337
azathioprine (321) 321
studies (320) 320
clinical trials (317) 317
immunosuppressive agents - administration & dosage (316) 316
methotrexate - therapeutic use (315) 315
antibodies (313) 313
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6615) 6615
Spanish (79) 79
Japanese (76) 76
German (73) 73
French (64) 64
Russian (49) 49
Italian (24) 24
Korean (21) 21
Hungarian (18) 18
Polish (11) 11
Danish (10) 10
Portuguese (9) 9
Chinese (5) 5
Turkish (4) 4
Hebrew (2) 2
Croatian (1) 1
Dutch (1) 1
Greek (1) 1
Icelandic (1) 1
Norwegian (1) 1
Romanian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Archives of Dermatological Research, ISSN 0340-3696, 1/2009, Volume 301, Issue 1, pp. 99 - 105
Drug-induced lupus erythematosus (DILE) is defined as a lupus-like syndrome temporally related to continuous drug exposure which resolves after discontinuation... 
Drug-induced lupus erythematosus | Antinuclear antibodies (ANA) | Medicine & Public Health | Dermatology | Anti-TNFα-induced lupus | Anti-histone antibodies | Subacute cutaneous drug-induced lupus (SCLE) | Drug reactions | RHEUMATOID-ARTHRITIS | AUTOANTIBODIES | NECROSIS-FACTOR-ALPHA | INDUCTION | DERMATOLOGY | Anti-TNF alpha-induced lupus | THERAPY | AUTOIMMUNITY | INFLIXIMAB | ETANERCEPT | ANTI-TNF-ALPHA | EPIDEMIOLOGY | Antifungal Agents - adverse effects | Antitubercular Agents - adverse effects | Naphthalenes - adverse effects | Antibodies - metabolism | Calcium Channel Blockers - adverse effects | Serositis | Exanthema | Humans | Isoniazid - adverse effects | Interferons - adverse effects | Antihypertensive Agents - administration & dosage | Sodium Chloride Symporter Inhibitors - adverse effects | Arthritis | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Lupus Erythematosus, Systemic - immunology | Sodium Chloride Symporter Inhibitors - administration & dosage | Tumor Necrosis Factor-alpha - immunology | Antibodies - immunology | Lupus Erythematosus, Cutaneous - chemically induced | Procainamide - administration & dosage | Lupus Erythematosus, Cutaneous - immunology | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Anti-Arrhythmia Agents - administration & dosage | Procainamide - adverse effects | Antihypertensive Agents - adverse effects | Hydralazine - adverse effects | Isoniazid - administration & dosage | Lupus Erythematosus, Systemic - diagnosis | Interferons - administration & dosage | Hydralazine - administration & dosage | Animals | Anti-Arrhythmia Agents - adverse effects | Naphthalenes - administration & dosage | Calcium Channel Blockers - administration & dosage | Antitubercular Agents - administration & dosage | Lupus Erythematosus, Systemic - chemically induced | Antifungal Agents - administration & dosage | Lupus Erythematosus, Cutaneous - diagnosis | Lupus | Antigen-antibody reactions | Enzymes | Antigens | Biological products | Antibodies | Viral antibodies | Enzyme inhibitors | Systemic lupus erythematosus | Fluocinolone acetonide | Calcium channel blockers | Diuretics | Kidney diseases | Hydralazine | Index Medicus
Journal Article
Gastroenterology, ISSN 0016-5085, 2008, Volume 134, Issue 7, pp. 1861 - 1868
Background & Aims: The benefit to risk ratio of concomitant immunosuppressives with scheduled infliximab (IFX) maintenance therapy for Crohn's disease is an... 
Gastroenterology and Hepatology | RHEUMATOID-ARTHRITIS | ANTIBODIES | MULTICENTER | INFLAMMATORY-BOWEL-DISEASE | THERAPY | SERUM INFLIXIMAB | LYMPHOMA | RISK | INDUCTION | GASTROENTEROLOGY & HEPATOLOGY | SHORT-TERM | Azathioprine - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gastrointestinal Agents - administration & dosage | Crohn Disease - metabolism | Male | Intestinal Mucosa - drug effects | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Infliximab | Adult | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Female | Drug Therapy, Combination | France | Gastrointestinal Agents - pharmacokinetics | Immunosuppressive Agents - administration & dosage | Drug Administration Schedule | Mercaptopurine - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Belgium | Antibodies, Monoclonal - administration & dosage | Crohn Disease - pathology | Crohn Disease - drug therapy | Methotrexate - administration & dosage | Gastrointestinal Agents - adverse effects | Infusions, Intravenous | Intestinal Mucosa - pathology | Clinical trials | Crohn's disease | C-reactive protein | Tumor necrosis factor | Immunotherapy | Life Sciences | Human health and pathology | Hépatology and Gastroenterology
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 10006, pp. 1825 - 1834
Journal Article
Journal Article
Spine, ISSN 0362-2436, 03/2012, Volume 37, Issue 6, pp. 439 - 444
Journal Article